Search / 9 results found

  • Updated

ANDOVER, Mass., Jan. 5, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the publication of OCS™ Liver PROTECT Trial Results in JAMA Surgery, a member of the Journal of the American Medical Association (JAMA) Network. The publication, titled Impact of Portable Normothermic Blood-Based Machine Perfusion on Outcomes of Liver Transplant, was published online on January 5, 2022. The OCS™ Liver System was approved by the U.S. Food and Drug Administration (FDA) for the preservation and assessment of donor livers for transplant from donors after brain death (DBD) and after circulatory death (DCD) on September 29, 2021.

  • Updated

BOSTON, Dec. 22, 2021 /PRNewswire/ -- Control of most bodily functions depends on the ability of cells to talk to each other. We have long known about two routes for cell-to-cell communication: the nervous system and the secretion of hormones. Over the past five years scientists recognized an important third route of communication based on exosomes—tiny sacs or vesicles containing protein and RNA molecules that cells secrete into circulation where they can be taken up by other cells to regulate metabolism.

  • Updated

FRAMINGHAM, Mass., Nov. 8, 2021 /PRNewswire/ -- Transplant Genomics ("TGI"), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, announces that the American Journal of Transplantation ("AJT") has published "Donor-Derived Cell-Free DNA Detects Early Evidence of Graft Injury in Stable Liver Transplant Recipients," by Josh Levitsky, MD, MS. The article will appear in Volume 21, Issue 9 of AJT.

CAMBRIDGE, Mass., Oct. 18, 2021 /PRNewswire/ -- Karallief®, Inc., a nutraceutical ingredient company that researches, develops, and distributes clinically studied combination herbal extract ingredient formulas, has published a study for its latest formula, KaraLiv™, showing this all-natural dietary supplement significantly promotes liver function in less than 30 days. Published in the International Journal of Basic & Clinical Pharmacology, this double-blind, parallel, placebo-controlled, randomized clinical trial found that KaraLiv™ safely, quickly and effectively supports liver function.